Skip to main content
. 2022 Jan 4;269(6):3276–3285. doi: 10.1007/s00415-021-10931-w

Table 3.

Adverse events of special interest (AESI) detected in the safety analysis set (n = 4067)

System Preferred term N (%) EAIR per year (95% CI)
Cardiac events Hypertension 255 (6.27%) 0.021 [0.018, 0.023]
Infections Herpes zoster 122 (3.0%) 0.010 [0.008, 0.011]
Progressive multifocal leukoencephalopathy 2 (0.05%) 0.000 [0.000, 0.001]
Meningitis, cryptococcal 1 (0.02%) 0.000 [0.000, 0.000]
Leukopenia Lymphopenia 477 (11.73%) 0.040 [0.037, 0.044]
Leukopenia 291 (7.16%) 0.024 [0.021, 0.027]
White blood cell count decreased 115 (2.83%) 0.009 [0.007, 0.011]
Diseases of the nervous system Posterior reversible encephalopathy syndrome 0 0.000 [0.000, 0.000]
Acute disseminated encephalomyelitis 0 0.000 [0.000, 0.000]
Hepatic enzymes Hepatic enzyme level increased 230 (5.66%) 0.018 [0.016, 0.021]
Alanine aminotransferase level increased 187 (4.60%) 0.015 [0.013, 0.017]
Eye disorder Macular edema 20 (0.49%) 0.002 [0.001, 0.002]
Neoplasms Thyroid cancer 1 (0.02%) 0.000 [0.000, 0.000]
Benign breast neoplasm 1 (0.02%) 0.000 [0.000, 0.000]
Benign neoplasm 1 (0.02%) 0.000 [0.000, 0.000]
Lymphoma Diffuse large B-cell lymphoma stage I 1 (0.02%) 0.000 [0.000, 0.000]
Follicle center lymphoma, follicular grade I, II, III stage IV 1 (0.02%) 0.000 [0.000, 0.000]
Non-Hodgkin’s lymphoma 1 (0.02%) 0.000 [0.000, 0.000]
Pregnancy Abortion spontaneous 7 (0.17%) 0.001 [0.000, 0.001]
Abortion 3 (0.07%) 0.000 [0.000, 0.001]
Abortion incomplete 1 (0.02%) 0.000 [0.000, 0.000]

EAIR exposure adjusted incidence rate